Arni Entresto denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for arni entresto are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Quantity for Entresto — and Why You Can Appeal

Blue Cross Blue Shield quantity-limit denials for Entresto (sacubitril/valsartan) typically reflect plan edits that cap the number of tablets or days' supply dispensed per fill cycle. These edits are designed to align dispensing with standard dosing schedules — but when your prescriber has documented a specific titration plan or a fill schedule that differs from the default limit, the plan's automated edit can fire incorrectly.

Do not accept this denial as final. Quantity-limit determinations are fully appealable under your plan's internal grievance process and, if internal appeal fails, through an independent external review.

## The Federal Appeal Framework

• ACA §2719 / PPACA External Review: Non-grandfathered individual and group health plans must offer independent external review. You typically have approximately four months (180 days) from the denial notice to request external review, though you should check your denial letter for the exact deadline.
• ERISA §503 (employer-sponsored plans): Entitles you to a full-and-fair review of any adverse benefit determination, with written explanation of the reasons and the specific plan provisions relied upon.
• Expedited review: If a standard timeline would seriously jeopardize your health, request an expedited internal appeal and expedited external review simultaneously — decisions are typically required within 72 hours.

## What to Gather

1. Prescriber's medical-necessity letter — should state the prescribed quantity, the clinical rationale (e.g., titration phase, pill burden, adherence considerations), and why the requested supply is medically necessary for your specific situation. 2. Titration or dosing plan documentation — chart notes confirming the prescriber's intended regimen and the phase of therapy you are in. 3. Diagnosis confirmation — records establishing the diagnosis and severity of heart failure (e.g., NYHA functional class documented in chart notes, most recent echocardiogram or functional assessment). 4. Prior fill history — pharmacy records showing any fills already dispensed, confirming you are not seeking duplicate supply. 5. BCBS's published quantity-limit criteria — obtain the plan's current coverage/medical policy for Entresto and copy the exact quantity-limit language into your appeal.

## Criteria-Mapping Structure

In your appeal letter, create a two-column table:

| BCBS Quantity-Limit Requirement (from policy) | How Your Chart Satisfies It | |---|---| | [Paste each requirement from the plan's published policy] | [Cite the specific chart note, date, and finding that meets it] |

Also reference the FDA-approved prescribing information for Entresto, which establishes the approved dosing and titration schedule. If your prescribed quantity is consistent with that label and your prescriber has documented the clinical reason, state this explicitly.

## Next Steps

File your internal appeal in writing, attach all documentation, and request a written decision with the specific clinical and policy basis for any continued denial. If the internal appeal is denied, escalate immediately to your state's external review organization (listed on your denial letter) or to the federal external review process.